Form 8-K - Current report:
SEC Accession No. 0001193125-24-226479
Filing Date
2024-09-26
Accepted
2024-09-26 07:07:00
Documents
13
Period of Report
2024-09-20
Items
Item 1.02: Termination of a Material Definitive Agreement

Document Format Files

Seq Description Document Type Size
1 8-K d855277d8k.htm   iXBRL 8-K 27472
  Complete submission text file 0001193125-24-226479.txt   145556

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA sage-20240920.xsd EX-101.SCH 2505
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE sage-20240920_lab.xml EX-101.LAB 17203
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE sage-20240920_pre.xml EX-101.PRE 10785
16 EXTRACTED XBRL INSTANCE DOCUMENT d855277d8k_htm.xml XML 3644
Mailing Address 55 CAMBRIDGE PARKWAY CAMBRIDGE MA 02142
Business Address 55 CAMBRIDGE PARKWAY CAMBRIDGE MA 02142 617-299-8380
Sage Therapeutics, Inc. (Filer) CIK: 0001597553 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36544 | Film No.: 241326173
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)